Clinical Trial Goal
To find out:
- The highest dose of AJ1-11095 that’s safe to give
- If AJ1-11095 is safe and works well to treat myelofibrosis that is refractory after treatment with a JAK2 inhibitor
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have been treated with a type 1 JAK2 inhibitor like ruxolitinib. Your doctor can tell you this
- Have not had your spleen removed
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
AJ1-11095 is a type 2 small molecule inhibitor that targets JAK2 on certain cells.
You’ll get:
You’ll get:
- AJ1-11095 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and scans to see how well the treatment is working. The clinical trial doctors will check your health for about 1 year.
The Food and Drug Administration (FDA) has not yet approved AJ1-11095.
Locations
Sponsors
lead: Ajax Therapeutics, Inc.
